Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19

Lilly’s combination therapy of two antibodies, bamlanivimab and etesevimab, helped cut the risk of hospitalization and death in Covid-19 patients by 70%, data from a late-stage trial showed in January